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Drug-eluting stent thrombosis
Abstract
Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is
associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents
(DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Patient-, lesion-, and procedure-related factors as well as thrombogenicity of the stent itself are involved
in the pathogenesis of stent thrombosis. Furthermore, early cessation of dual antiplatelet therapy
correlates with an increased risk of stent thrombosis. This review focuses on clinical evidence and
pathophysiological mechanisms of stent thrombosis with DES, particularly highlighting prothrombotic
effects of the stent itself.
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ABSTRACT 
 
Stent thrombosis is a rare complication following stent implantation; if it occurs, 
however, it is associated with a high morbidity and mortality. Despite reduced rates of 
restenosis, drug-eluting stents (DES) have not reduced the incidence of stent 
thrombosis as compared to bare-metal stents (BMS). Patient-, lesion-, and 
procedure-related factors as well as thrombogenicity of the stent itself are involved in 
the pathogenesis of stent thrombosis. Furthermore, early cessation of dual 
antiplatelet therapy correlates with an increased risk of stent thrombosis. This review 
focuses on clinical evidence and pathophysiological mechanisms of stent thrombosis 
with DES, particularly highlightening prothrombotic effects of the stent itself. 
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CLINICAL EVIDENCE 
 
Percutaneous coronary intervention (PCI) is a routine interventional 
procedure for treating acute coronary syndromes. The use of bare-metal stents 
(BMS) reduced restenosis rates as compared to angioplasty alone from ≈40% to 
≈20% [Babapulle et al. 2004; Grines et al. 1999]. Drug-eluting stents (DES), coated 
with antiproliferative agents such as rapamycin or paclitaxel, further decreased rates 
of restenosis to less than 10% and improved the outcome after coronary artery 
stenting [Babapulle et al. 2004; Windecker et al. 2005].  
However, major concerns emerged about the safety of DES, particularly 
regarding the incidence of stent thrombosis [Camenzind et al. 2007; Daemen et al. 
2007; Lagerqvist et al. 2007; Mauri et al. 2007; Pfisterer et al. 2006]. Despite reduced 
rates of restenosis, the incidence of stent thrombosis may be higher with DES as 
compared to BMS. In particular, late stent thrombosis can occur months or even 
years after stent deployment in patients treated with DES [McFadden et al. 2004; 
Daemen et al. 2007; Holmes et al. 2007; Lüscher et al. 2007]. 
The incidence of stent thrombosis with BMS was reported to be ≈1% 
[Babapulle et al. 2004; Cutlip et al. 2001; Holmes et al. 2007]. BMS thrombosis 
mostly occurred within the first 30 days after implantation; however, late thrombotic 
events have been documented as well [Doyle et al. 2007; Stone et al. 2007]. During 
the first months after stent deployment, the rates of stent thrombosis did not differ 
between patients treated with BMS and those treated with DES [Iakovou et al. 2005; 
Moreno et al. 2005; Ong et al. 2005; Windecker et al. 2005]; the incidence was 1.0% 
to 1.5% within the first 30 days, and 0.5% between 1 and 9 months. However, in the 
BASKET (Basel Stent Kosten Effektivitäts Trial)-LATE trial, late stent thrombosis was 
observed twice as frequently after DES deployment as compared to BMS, particularly 
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following cessation of antiplatelet therapy. In this trial, the incidence of thrombosis 
was 2.6% in DES versus 1.3% in BMS between 7 and 18 months after stent 
deployment [Pfisterer et al. 2006].  
Recent data indicate that stent thromboses with DES do indeed continue to 
occur steadily. Rates of 0.3-1.1% per year for at least up to 3 years after stent 
implantation have been observed [Daemen et al. 2007; de la Torre-Hernàndez et al. 
2008; Flores-Ríos et al. 2008]. However, the true incidence of late thrombosis is not 
clear to date. 
Stent thrombosis is a relatively rare complication after stent implantation; 
however, given the large number of coronary interventions and the serious nature of 
this complication, it remains a major concern [Holmes et al. 2007; Iakovou et al. 
2005]. Cardiac death and myocardial infarction have been observed in 4.9% of 
patients after DES deployment as compared to 1.3% after BMS deployment 7 to 18 
months after stenting, possibly related to late stent thrombosis [Pfisterer et al. 2006]. 
Consistently, in a large clinical registry, an increased risk of cardiac death and 
myocardial infarction was observed 6 months to 3 years after DES implantation when 
compared to BMS [Lagerqvist et al. 2007]. However, after long-term follow-up, the 
overall incidence of cardiac death and myocardial infarction was reported to be 
similar in both stent groups [Lagerqvist et al. 2007; Pfisterer et al. 2006; Spaulding et 
al. 2007; Stettler et al. 2007]. These findings have been related to increased rates of 
death and myocardial infarction during the initial 30 days as well as higher rates of 
restenosis related cardiac events after BMS deployment [Doyle et al. 2007; 
Lagerqvist et al. 2007; Pfisterer et al. 2006; Spaulding et al. 2007].  
Stent implantation for off-label indications such as restenotic lesions, 
bypass graft lesions, left main coronary artery disease, as well as ostial, bifurcated, 
and totaly occluded lesions is common practice. Off-label use of both, DES and BMS, 
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has been associated with higher rates of ischemic complications as compared with 
standard indications [Beohar et al. 2007; Win et al. 2007; Marroquin et al. 2008]. 
However, among patients with off-label indications, the incidence of death and 
myocardial infarction was reported to be similar in both stent groups 1 year after stent 
deployment [Marroquin et al. 2008]. These findings suggest that the poorer outcome 
observed after stenting for off-label indications are related to patient and lesion 
characteristics but not to the stent itself. As observed with standard indications, DES 
implantation may be associated with lower rates of repeated revascularization as 
compared with BMS [Marroquin et al. 2008]. Hence, large long-term randomized 
clinical trials including different clinical subsets of patients undergoing DES 
deployment for standard indications as well as for off-label use are needed to 
ascertain the safety of DES and fully assess the risk of late stent thrombosis.  
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PATHOPHYSIOLOGICAL MECHANISMS 
 
Several factors are involved in the pathogenesis of stent thrombosis 
[Figure 1] . Patient-related factors such as diabetes mellitus, renal failure, advanced 
age, low ejection fraction, and stenting in acute coronary syndromes are associated 
with an increased risk of stent thrombosis [Iakovou et al. 2005]. Furthermore, 
advanced age seems to be a risk factor for subacute stent thrombosis, whereas 
younger age has been associated with late stent thrombosis [de la Torre-Hernàndez 
et al. 2008]. Lesion-related factors such as bifurcation lesions, lesion length, and 
restenosis lesions also promote the occurrence of thrombotic events; moreover, 
procedure-related factors such as stent malapposition, subexpansion, overlapping 
stent placement, and coronary artery dissection predispose to stent thrombosis [Farb 
et al. 2003; Iakovou et al. 2005; Joner et al. 2006; Finn et al. 2007]. Indeed, 
incomplete stent apposition has been observed more frequently after DES 
implantation as compared to BMS, which may further contribute to late thrombotic 
events [Hong et al. 2006; Qian et al. 2008]. 
 
Discontinuation of Antiplatelet Therapy 
Dual antiplatelet therapy with clopidogrel and acetylsalicylic acid plays a 
key role in reducing the incidence of thrombotic events, associated death, and 
myocardial infarction after stent implantation [Grines et al. 2007; Eisenstein et al. 
2007]. Particularly during the first 6 to 12 months after stent deployment, 
discontinuation of dual antiplatelet therapy has been shown to increase the risk of 
DES thrombosis [McFadden et al. 2004; Windecker et al. 2007]. However, cessation 
of clopidogrel has recently been associated with higher rates of death and myocardial 
infarction 2 years after DES deployment [Eisenstein et al. 2007]. Furthermore, stent 
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thromboses have been observed after interruption of longterm antiplatelet 
monotherapy [Flores-Ríos et al. 2008; McFadden et al. 2004]. In addition, 
nonresponsiveness to antiplatelet therapy may further promote thrombus formation 
after stent implantation [Grubel et al. 2007]. 
At present, a course of 12 months of dual antiplatelet therapy with 
clopidogrel and acetylsalicylic acid may be considered. Dual antiplatelet therapy with 
prasugrel for 6 to 15 months was recently shown to reduce the incidence of stent 
thrombosis, cardiovascular death, myocardial infarction, and stroke as compared to 
clopidogrel [Wiviott et al. 2008]. Hence, optimal antiplatelet therapy, its duration, and 
the use of BMS if contraindications prevent dual antiplatelet therapy remain to be 
determined to reduce the incidence of stent thrombosis. 
 
Inflammatory Reaction to the Stent 
 
Stent length and strut thickness correlate with an increased risk of stent 
thrombosis. As shown in autopsy studies, inflammatory reactions predominantly 
mediated by CD45-positive leucocytes and eosinophils take place after stent 
implantation. Eosinophilic infiltrates around struts reflect a hypersensitivity reaction to 
the stent, most likely the polymer [Nebeker et al. 2006; Virmani et al. 2004]; however, 
reactions to the metal struts or the loaded drugs may also contribute. Indeed, 
inflammatory reactions are more pronounced after DES implantation as compared 
with BMS [Farb et al. 2003; Joner et al. 2006; Finn et al. 2007]. In the rabbit iliac 
artery stenting model, stronger inflammatory reactions, more fibrin deposition, and an 
incomplete reendothelialization are observed after DES implantation as compared to 
BMS [Finn et al. 2005]. Hence, inflammatory response and hypersensitivity reaction 
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to the stent delay vascular healing and may thereby favor thrombotic events, 
particularly after DES deployment. 
 
Impaired Reendothelialization 
 
Stent deployment causes endothelial denudation and exposes 
thrombogenic material to the circulating blood. Hence, complete reendothelialization 
of the stented segment is crucial for vessel healing. Reendothelialization is 
completed 2 weeks after BMS implantation in the porcine coronary artery and 3 to 4 
weeks after BMS deployment in the rabbit iliac artery [Finn et al. 2007]. In contrast, 
only 40% to 60% of the stent surface is reendothelialized after DES deployment at 
the same time points [Finn et al. 2005 and 2007]. Angioscopic findings in humans 
revealed that complete reendothelialization was achieved 3 to 6 months after BMS 
deployment, whereas the majority of rapamycin-eluting stents exhibited incomplete 
neointimal coverage [Kotani et al. 2006]. These findings were complemented by 
human autopsy studies showing impaired arterial healing characterized by 
incomplete reendothelialization and persistent fibrin deposition after DES 
implantation as compared to BMS [Joner et al. 2006; Finn et al. 2007].  
The macrocyclic lactone rapamycin and the microtubule-stabilizing agent 
paclitaxel are both used on first-generation DES and reduce restenosis by inhibiting 
vascular smooth muscle cell proliferation as well as migration [Parry et al. 2005; 
Sollott et al. 1995]. Everolimus and zotarolimus, used on second-generation DES, 
exert a similar inhibitory effect on vascular smooth muscle cell activation [Farb et al. 
2002; Garcia-Touchard et al. 2006].  
Since these drugs do not act in a cell-type specific manner, it is 
conceivable that agents eluted from DES do not only affect vascular smooth muscle 
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cells, but also alter the biology of endothelial cells. In addition to their effect on 
vascular smooth muscle cells, rapamycin, paclitaxel, and zotarolimus do indeed 
inhibit proliferation and migration of endothelial cells [Matter et al. 2006; Parry et al. 
2005; Steffel et al. 2005; Garcia-Touchard et al. 2006]. Thus, agents eluted from DES 
impair endothelial regeneration by inhibiting proliferation and migration of these cells, 
and the impaired endothelial coverage after stent deployment leaves the 
thrombogenic stent struts in contact with the circulating blood favoring the 
development of thrombosis.    
Endothelial progenitor cells are the circulating precursors of mature 
endothelial cells and contribute to neovascularization and healing at sites of 
endothelial damage. Hence, a crucial role has been ascribed to these cells in the 
process of reendothelialization [Blindt et al. 2006; Griese et al. 2003]. Interestingly, 
rapamycin negatively affects proliferation, migration, and differentation of human 
endothelial progenitor cells [Butzal et al. 2004; Chen et al. 2006]. Thus, drugs eluted 
from DES may further delay vascular healing by impairing proper function of 
endothelial progenitor cells.  
 
Enhanced Tissue Factor Expression 
 
Given the important role of tissue factor (TF) as the principal trigger of 
coagulation, TF may also be involved in the pathogenesis of stent thrombosis [Steffel 
et al. 2006; Steffel et al. 2007]. Both rapamycin and paclitaxel do indeed enhance TF 
expression and activity under inflammatory conditions; rapamycin enhances 
thrombin- and TNF-α-induced TF expression via inhibition of the mammalian target of 
rapamycin (mTOR) [Steffel et al 2005], whereas paclitaxel increases TF expression 
via c-Jun terminal NH2 kinase (JNK) activation [Figure 2] [Stähli et al. 2006]. 
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Interestingly, both rapamycin and paclitaxel also increase plasminogen activator 
inhibitor (PAI)-1 expression in human coronary artery endothelial cells [Muldowney et 
al. 2007]. Because of their lipophilic properties, both rapamycin and paclitaxel 
accumulate in the vessel wall, reaching particularly high concentrations in the intima 
[Creel et al. 2000; Suzuki et al. 2001]. The concentrations exerting increased TF 
expression are indeed comparable with local tissue concentrations encountered after 
stent deployment. Furthermore, the drugs remain detectable for up to 12 weeks after 
stent deployment in vivo [Vogt et al. 2004]; therefore, the time course of 
reendothelialization coincides with the presence of the drugs in the vessel wall after 
stenting.  
Hence, these data suggest that both rapamycin and paclitaxel may 
indeed promote thrombus formation and favor stent thrombosis in vivo not only by an 
enhanced TF expression, but also by a diminished fibrinolysis, particularly when 
antithrombotic drugs are withdrawn, or when cytokine levels are elevated, as it 
occurs in acute coronary syndromes. 
 
Vasoconstriction after DES deployment 
 
In addition to these findings, DES, unlike BMS, can impair the endothelial 
response to acetylcholine- and exercise-mediated vasodilation in vessel segments 
adjacent to the stent, promoting endothelial dysfunction [Hofma et al. 2006; Togni et 
al. 2007]. However, underlying atherosclerotic disease in adjacent vessel segments 
may have contributed to these findings [Nakazawa et al. 2008]. Vasoconstriction 
alters coronary flow velocity and may thereby further promote thrombotic events; 
however, clinical consequences of these findings are still uncertain. 
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FUTURE STENT DESIGN 
 
The optimal DES prevents restenosis and at the same time accelerates 
reendothelialization. Hence, much effort is made to investigate novel agents for 
coating DES in addition to improving the polymers as well as the drug-release profile. 
Promising results have been observed after bioabsorbable drug-eluting stent 
implantation. Similar rates of restenosis and major adverse cardiac events have been 
reported after bioabsorbable DES deployment as compared to durable polymer DES 
[Ormiston et al. 2008]. In the porcine coronary artery stenting model, stents covered 
with integrin-binding cyclic Arg-Gly-Asp peptides promote reendothelialization by 
enhancing the recruitment of endothelial progenitor cells [Blindt et al. 2006]. Similar 
results have been observed after coating stents with antibodies against CD34 to 
capture endothelial progenitor cells [Aoki et al. 2005]. Titanium-nitride-oxide coated 
stents diminish platelet adhesion, reduce fibrinogen binding, and decrease rates of 
restenosis and major adverse cardiac events as compared with BMS [Windecker et 
al. 2005]. Dimethyl sulfoxide (DMSO) seems to be a promising agent for use on DES 
as well. DMSO inhibits VSMC proliferation and migration, and, in contrast to 
rapamycin and paclitaxel, decreases TF expression in endothelial cells, vascular 
smooth muscle cells, and monocytes; furthermore, intraperitoneal application of 
DMSO prevents thrombotic occlusion in vivo in a mouse model of photochemical 
carotid artery injury [Camici et al. 2006]. Cardiac glycosides may represent another 
candidate drug to be applied on DES as they exert antiproliferative effects on VSMC 
and at the same time decrease TF expression [Stähli et al. 2007]. However, further 
studies are needed to evaluate the efficacy and safety of these promising 
approaches. 
 12
CONCLUSIONS 
 
Stent thrombosis is a rare, but severe complication following stent 
implantation. Early discontinuation of dual antiplatelet therapy has clearly been 
correlated with an increased risk of stent thrombosis and seems to be a key predictor 
of thrombotic events. Patient-, lesion-, and procedure-related factors as well as the 
stent itself are involved in the pathogenesis of stent thrombosis. DES indeed exert 
prothrombogenic effects as they delay reendothelialization by inhibiting proliferation 
and migration of endothelial cells, impairing recruitment of endothelial progenitor 
cells, and enhancing TF expression. Hence, there is good reason for improvement of 
current DES, not only by developing novel polymers and improving drug release 
profiles, but also by identifying new drugs suitable for application on stents.  
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FIGURE LEGENDS 
 
Figure 1: Pathophysiological mechanisms of stent thrombosis after drug-eluting stent 
(DES) deployment. Procedure-related factors such as stent malapposition predispose 
to stent thrombosis. Eosinophilic infiltrates around stent struts reflect a 
hypersensitivity reaction, probably to the polymer, which delays vascular healing. The 
drugs released from the stent delay reendothelialization by inhibiting proliferation and 
migration of endothelial cells, impair the function of endothelial progenitor cells, and 
enhance expression of tissue factor (TF), all of which favor thrombus formation. 
 
Figure 2: Rapamycin enhances tissue factor (TF) expression via inhibition of the 
mammalian target of rapamycin (mTOR), whereas paclitaxel increases TF 
expression by enhanced c-Jun terminal NH2 kinase (JNK) activation. 
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